Stocks Under $0.10: ITRM, AMLM, BFRG, QNCX, ADMQ March Madness Watch

A group of sub-$0.10 and low-priced small-cap stocks is drawing increased attention as investors rotate into high-beta, low-float names across biotechnology, artificial intelligence, and critical minerals. With volatility rising and capital flowing into speculative growth themes, several companies are emerging on trader and investor watchlists.

Biotech Momentum: Iterum Therapeutics (NASDAQ: ITRM)

Biotech names ITRM have seen increased activity, moving sharply in pre-market trading as investors target rare-disease and orphan-drug opportunities. The company's focus on late-infantile neuronal ceroid lipofuscinosis (LINCL) and related pediatric neurodegenerative disorders positions it within a niche where limited treatment options and orphan-drug economics can drive outsized valuation shifts on clinical progress.

Critical Minerals & Supply Chain Theme: American Lithium Minerals (OTC: AMLM)

AMLM continues to gain traction as a diversified critical minerals explorer with exposure to lithium, gold, silver, copper, and rare earth elements. The company's Nevada lithium asset has recently been validated through independent analysis, while its broader portfolio spans Quebec polymetallic projects, Chile copper and silver assets, and international gold exposure.

With increasing focus on U.S. supply-chain security, EV batteries, AI infrastructure, and electrification metals, AMLM's multi-commodity approach helps reduce risk while maintaining upside exposure. Rising trading activity and a low public float structure have also placed the stock on momentum watchlists.

AI Meets Drug Discovery: BullFrog AI Holdings (NASDAQ: BFRG)

BullFrog AI is gaining visibility after announcing a commercial agreement with a top 5 global pharmaceutical company to apply its bfLEAP Registered AI platform to identify and prioritize drug targets in major depressive disorder (MDD). The deal includes exclusive access to a target candidate, highlighting the growing role of AI and machine learning in accelerating drug discovery.

Balance Sheet Reset: Quince Therapeutics (NASDAQ: QNCX)

Quince Therapeutics recently announced the settlement of its European Investment Bank loan for $5.5 million, removing a key financial overhang. Balance sheet improvements are often closely watched in small-cap biotech, particularly as companies reposition for clinical advancement and strategic flexibility.

Earnings Catalyst Ahead: ADM Endeavors (OTCQB: ADMQ)

ADM Endeavors remains on watch ahead of its March 2026 earnings report, following its expansion into a 100,000-square-foot $13M production facility designed to significantly increase output capacity. Growth in manufacturing apparel and custom promotional products continues to support the company's expansion strategy.

The Bigger Picture

Across sectors, a common theme is emerging:low-priced, low-float stocks with defined catalysts are regaining attention.

* Biotech right rare disease and AI-driven drug discovery
* Critical minerals right EVs, energy transition, supply chains
* Small-cap growth right earnings expansion and balance sheet resets

Most early-stage moves begin quietly-before broader participation follows.

As volatility and sector rotation continue, these stocks under $0.10 represent a cross-section of where speculative capital is beginning to flow.

Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors with a safe harbor with regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, and assumptions about future events or performance are not statements of historical fact and may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or due to the speculative nature of the companies profiled. TheStreetReports (TSR) is responsible for the production and distribution of this content."TSR" is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. "TSR" authors, contributors, or its agents, may be compensated for preparing research, video graphics, podcasts and editorial content. "TSR" has not been compensated to produce content related to "Any Companies" appearing herein. As part of that content, readers, subscribers, and everyone viewing this content are expected to read the full disclaimer in our website.

Media Contact
Company Name: The Street Reports
Contact Person: Editor
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=stocks-under-010-itrm-amlm-bfrg-qncx-admq-march-madness-watch]
Country: United States
Website: http://www.thestreetreports.com

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.